# US 2016/0354336 A1 · Taxane Particles and Their Use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0354336 A1
- Document ID: US20160354336A1
- Status: Published application
- Kind: A1
- Application number: 15/174,505
- Filed: 2016-06-06
- Published: 2016-12-08
- Earliest claimed: 2015-06-04
- Assignees: Crititech, Inc.
- Applicants: Crititech, Inc.
- Inventors: Michael BALTEZOR; Joseph FARTHING; Jake SITTENAUER; Jahna ESPINOSA; Samuel CAMPBELL; Matthew MCCLOREY; Julia K. FISCHER; Mark D. WILLIAMS
- Web page: https://patentgrep.com/patent/US20160354336A1

## CPC

- A61K 31/337: having four-membered rings, e.g. taxol
- A61J 3/02: into the form of powders (pulverising in general B02C)
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/10: Dispersions; Emulsions
- A61K 9/14: Particulate form, e.g. powders, {Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles (microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51)}
- A61K 9/1605: {Excipients; Inactive ingredients}
- A61K 9/1682: {Processes}
- A61K 9/1688: {resulting in pure drug agglomerate optionally containing up to 5% of excipient}
- A61K 9/5192: {Processes}
- A61P 35/00: Antineoplastic agents
- B01D 46/24: Particle separators, e.g. dust precipitators, using rigid hollow filter bodies
- B01J 2/04: in a gaseous medium {(if combined with suspending the material in a gas, e.g. fluidised beds B01J2/16)}
- B01J 3/008: {Processes carried out under supercritical conditions}
- B01J 3/02: Feed or outlet devices therefor
- B01J 4/002: {Nozzle-type elements (nozzle-type reactors B01J19/26)}
- B01J 19/10: employing sonic or ultrasonic vibrations
- B01J 19/26: Nozzle-type reactors, i.e. the distribution of the initial reactants within the reactor is effected by their introduction or injection through nozzles
- B05B 1/3489: {Nozzles having concentric outlets}
- B05B 13/0278: {Arrangement or mounting of spray heads (B05B13/0207 takes precedence)}
- B01D 2271/02: Gaskets, sealings
- B05D 2401/90: at least one component of the composition being in supercritical state or close to supercritical state
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61J: CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- B01D: SEPARATION (separating solids from solids by wet methods B03B, B03D; by pneumatic jigs or tables B03B; by other dry methods B07; magnetic or electrostatic separation of solid materials from solid materials or fluids, separation by high-voltage electric fields B03C; centrifuges, vortex apparatus B04; presses per se for squeezing-out liquid from liquid-containing material B30B9/02; treatment of water C02F, e.g. softening by ion-exchange C02F1/42; {arrangements of air intake cleaners in gas turbine plants F02C7/05} ; arrangements or mounting of filters in air-conditioning, air-humidification or ventilation F24F13/28)
- B01J: CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B05B: SPRAYING APPARATUS; ATOMISING APPARATUS; NOZZLES (spray-mixers with nozzles B01F25/72; processes for applying liquids or other fluent materials to surfaces by spraying B05D)
- B05D: PROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL (conveying articles or workpieces through baths of liquid B65G, e.g. B65G49/02)

## Abstract

Compositions are provided that include having at least 95% by weight of a taxane, or a pharmaceutically acceptable salt thereof, where the particles have a mean bulk density between about 0.050 g/cm3 and about 0.15 g/cm3, and/or a specific surface area (SSA) of at least 18 m2/g, 20 m2/g, 25 m2/g, 30 m2/g, 32 m2/g, 34 m2/g, or 35 m2/g. Methods for making and using such compositions are also provided.

## Claims

### Claim 1

A composition, comprising particles including at least 95% by weight of a taxane, or a pharmaceutically acceptable salt thereof, wherein the particles have one or both of the following characteristics:
(i) a mean bulk density between about 0.050 g/cm3 and about 0.15 g/cm3, and/or
(ii) have a specific surface area (SSA) of at least 18 m2/g.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the taxane is selected from the group consisting of paclitaxel, docetaxel, cabazitaxel, taxadiene, baccatin III, taxchinin A, brevifoliol, and taxuspine D, or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 2)

The composition of claim 2, wherein the taxane is paclitaxel or a pharmaceutically acceptable salt thereof, and wherein the particles have a mean bulk density between about 0.050 g/cm3 and about 0.12 g/cm3.

### Claim 4 (depends on 3)

The composition of claim 3, wherein the paclitaxel particles have a specific surface area (SSA) of at least 18 m2/g.

### Claim 5 (depends on 3)

The composition of claim 3, wherein the paclitaxel particles have a SSA of between about 22 m2/g and about 40 m2/g.

### Claim 6 (depends on 3)

The composition of claim 3, wherein at least 40% (w/w) of the paclitaxel is dissolved in 30 minutes or less in a solution of 50% methanol/50% water (v/v) at 37° and pH 7.0 in a USP II paddle apparatus operating at 75 RPM.

### Claim 7 (depends on 2)

The composition of claim 2, wherein the taxane is docetaxel or a pharmaceutically acceptable salt thereof, and wherein the particles have a mean bulk density between about 0.050 g/cm3 and about 0.12 g/cm3.

### Claim 8 (depends on 7)

The composition of claim 7, wherein the docetaxel particles have a SSA of at least 18 m2/g.

### Claim 9 (depends on 8)

The composition of claim 8, wherein the docetaxel particles have a SSA of between about 40 m2/g and about 50 m2/g.

### Claim 10 (depends on 7)

The composition of claim 7, wherein at least 20% (w/w) of the docetaxel is dissolved in 30 minutes or less in a solution of 15% methanol/85% water (v/v) at 37° and pH 7.0 in a USP II paddle apparatus operating at 75 RPM.

### Claim 11

A composition, comprising
(a) particles including at least 95% by weight of paclitaxel, wherein at least 40% (w/w) of the paclitaxel is dissolved in 30 minutes or less in a solution of 50% methanol/50% water (v/v) at 37° and pH 7.0 in a USP II paddle apparatus operating at 75 RPM; or
(b) at least 95% by weight of docetaxel, wherein at least 20% (w/w) of the docetaxel is dissolved in 30 minutes or less in a solution of 15% methanol /85% water (v/v) at 37° and pH 7.0 in a USP II paddle apparatus operating at 75 RPM.

### Claim 12 (depends on 1)

The composition of claim 1, wherein the particles have a mean particle size of between about 0.4 μm and about 1.2 μm.

### Claim 13 (depends on 1)

The composition of claim 1, wherein the composition comprises a suspension further comprising a pharmaceutically acceptable aqueous carrier.

### Claim 14 (depends on 1)

The composition of claim 1, wherein the particles comprise at least 98% by weight of the compound.

### Claim 15 (depends on 1)

A method for treating a tumor, comprising administering to a subject with a tumor an amount effective to treat the tumor of the composition of claim 1.

### Claim 16 (depends on 16)

The method of claim 16, wherein the tumor is selected from the group consisting of a breast tumor, an ovarian tumor, a lung tumor, a bladder tumor, a prostate tumor, a bone tumor, a stomach tumor and a pancreatic tumor.

### Claim 17 (depends on 15)

The method of claim 15, wherein the composition is administered intraperitoneally.

### Claim 18 (depends on 17)

The method of claim 17, wherein the composition is administered by perfusion or as a bolus into the peritoneal cavity.

### Claim 19 (depends on 15)

The method of claim 15, wherein the subject is a human subject.

### Claim at position 20

20-30. (canceled)
